Autopsy report · NCT02260648

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

“Study termination due to insufficient efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 10 months before it stopped.
• 149 participants enrolled.
• Results were posted on the registry 2 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Hypercholesterolemia

Interventions

Evacetrapib; Ezetimibe; Atorvastatin; Placebo

Participants

149

Sites

8

Countries

Japan

Trials that died the same way

• A Study of Tadalafil for Duchenne Muscular Dystrophy
  “The study is being terminated for lack of efficacy” (85% match in meaning)
• Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
  “Study was terminated early due to a lack of improved efficacy.” (84% match in meaning)
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (84% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (83% match in meaning)
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.